Biotech Values

[DewDiligence]

LLY retatrutide—(a/k/a “3G”)—shows respectable weight loss—but high dropout rate—in phase-3 trial for osteoarthritis pain:

https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-weight-loss-of-up-to-an-average-of-71-2-lbs-along-with-substantial-relief-from-osteoarthritis-pain-in-first-successful-phase-3-trial-302638804.html

LLY is up slightly in the PM session.